On the back of promises to corporation tax and end hefty fines for US businesses that wish to bring money in from offshore, the rumours of a series of pharma mega mergers has spread like wildfire throughout the sector. For cash-rich, big pharma companies such as Merck, Pfizer and Johnson & Johnson, this big business world could be exactly what their divide and conquer strategy has been waiting for and in a spend money to make money boom, this could mean a string of acquisitions not yet seen to date.
Not only has Trump's tax cutting policies caused a stir, but his support for a free-market approach and threat to import cheap generics. These controversial promises could all mean a new fertile land for innovation in the US, the result of which could be of huge importance to pharma. Whatever the change may be, change is definitely coming to the U S of A.